



Increase in migraine prevalence in the Danish adult population: a prospective longitudinal population-based study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-000962
Article Type:	Research
Date Submitted by the Author:	02-Mar-2012
Complete List of Authors:	Le, Han; Glostrup Hospital, Neurology, Danish Headache Center Tfelt-Hansen, Peer; Glostrup Hospital, Neurology, Danish Headache Center Skytthe, Axel; University of Southern Denmark, Epidemiology, Institute of Public Health, The Danish Twin Registry Kyvik, Kirsten; University of Southern Denmark, Institute of Regional Health Services Research; Odense University Hospital, Odense Patient data Explorative Network (OPEN) Olesen, Jes; Glostrup Hospital, Neurology, Danish Headache Center
Primary Subject Heading:	Neurology
Secondary Subject Heading:	Epidemiology
Keywords:	Migraine < NEUROLOGY, EPIDEMIOLOGY, Adult neurology < NEUROLOGY

SCHOLARONE™
Manuscripts

Increase in migraine prevalence in the Danish adult population: a prospective longitudinal population-based study

Han Le¹, Peer Tfelt-Hansen¹, Axel Skytthe², Kirsten Ohm Kyvik^{3,4} and Jes Olesen¹

- 1) The Danish Headache Centre, Department of Neurology, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark.
- 2) The Danish Twin Registry, Epidemiology, Institute of Public Health, University of Southern Denmark, Odense, Denmark.
- 3) Institute of Regional Health Services Research, University of Southern Denmark, Odense, Denmark.
- 4) Odense Patient data Explorative Network (OPEN), Odense University Hospital, Odense, Denmark.

Corresponding author:

Jes Olesen, professor, DMSc

Danish Headache Center

Department of Neurology

Glostrup Hospital

DK-2600 Glostrup

Denmark

E-mail: jeol@regionh.dk

Phone: +45 38633036

Fax: +45 38633970

Keywords: migraine, epidemiology, prevalence, incidence, longitudinal study

Word count: 2674 (max 3000)

Abstract

Objective: It is uncertain whether migraine prevalence has increased in modern society. Our aim was to assess any change in migraine prevalence over an 8 year period among the adult population in Denmark. **Design:** Prospective longitudinal population-based study. **Setting:** 30,000 twin individuals were invited to participate in two cross-sectional questionnaire surveys containing validated questions to diagnose migraine in 1994 and 2002. The twins are representative of the Danish population with regard to migraine and other somatic diseases. **Participants:** The 1994 cohort comprised 28,571 twin individuals aged 12 to 41 and the 2002 cohort 31,865 twin individuals aged 20 to 71. **Outcome measures:** sex-specific, age-specific and subtype-specific incidence and lifetime prevalence as well as 1-year prevalence of migraine. **Results:** 1 year prevalence in 2002 was 12.3% for migraine, 4.1% for migraine with aura (MA) and 8.2% for migraine without aura (MO). Lifetime prevalence of migraine was 16.1% in 1994 (aged 12 to 41) and 25.2% in 2002 (aged 20 to 71). Lifetime prevalence of migraine for age 20 to 41 was increased from 1994 to 2002 (18.5% vs. 24.5%) by 32.2% (95% CI: 27.0 to 37.3%; $p < 0.001$). The difference was primarily seen in the population older than 32 years. The increase was especially evident in MA (5.6% vs. 9.4%, $p < 0.001$) but also a significant increase in MO was found (13.0% vs. 15.1%, $p < 0.001$). 8-year period incidence rate of migraine was 0.141 corresponding to an average annual incidence rate of 17.6 per 1000 person years. **Conclusions:** Lifetime prevalence of migraine in Denmark increased substantially from 1994 to 2002. Part of the increase may be due to increased medical consultation resulting in increased rate of physician diagnosis or awareness due to previously participation in the 1994 survey. It is pertinent to study the environmental causes of the increase and to implement preventive measures.

Word count of abstract: 300 (max 300)

Introduction

Migraine was in 2001 ranked by the World Health Organization as the 19th of disabling diseases[1] causing great societal costs. In 2010, the total societal cost in Europe was estimated to be € 18.5 billion per year for the 50 million migraine sufferers. Migraine prevalence has been assessed in several large-scale population-based studies[3-4] but studies of incidence are sparse. It is uncertain whether migraine prevalence has increased in modern society. Replicate studies of migraine prevalence in the adult population using the same methodology at all evaluations showed conflicting results.[5-9] Furthermore, only few studies have distinguished between migraine with aura and migraine without aura.

“The Danish Twin Omnibus 1994 and 2002” were questionnaire studies among almost 30,000 and 35,000 twin individuals, respectively.[10-11] Both studies used the same validated questions to diagnose migraine and its subtypes. In the present publication the twin status is disregarded and the material is presented as a random sample from the Danish population, which is acceptable since these twins are representative of the whole Danish population with regard to migraine.[12]

The aim of our study was to estimate sex-specific, age-specific and subtype-specific incidence and lifetime prevalence as well as 1-year prevalence of migraine and to assess any change in migraine prevalence over an 8-year period among the young adult population in Denmark.

Material and methods

The study populations were based on twin cohorts enrolled in the Danish Twin Registry (DTR), one of the oldest and most complete population-based twin registries in the world.[10] The ascertainment of twins enrolled in this study was done using the Danish Civil Registration System as primary source. This system had since April 1st 1968 registered all

1
2
3 persons living in Denmark.[10-11,13] The twin cohorts from 1953 to 1982 were identified in
4
5 1991 by the mother assuming that a woman had twins if she gave birth to more than one child
6
7 within three consecutive days.[14] Identification of twins born between 1931 and 1952 was
8
9 based on an algorithm extracting all persons born on the same date, in the same parish and
10
11 with the same historical surname.[10] The DTR is validated and representative of the Danish
12
13 population as a whole.[12,15-17] The lifetime and 1-year prevalence of migraine did not
14
15 differ in monozygotic twins, dizygotic twins and single individuals.[12] The twins were
16
17 therefore regarded as single individuals in the present study.
18
19

20
21 The “Twin Omnibus 1994” comprised twin individuals from the cohorts 1953 to 1982 and
22
23 the “Twin Omnibus 2002” twin individuals from the cohorts 1931 to 1982. The
24
25 questionnaires investigated self-reported migraine identified based on the following
26
27 questions:
28

- 29
30 1. Have you ever had migraine?
31
32 2. Have you ever had visual disturbances that lasted from 5 to 60 minutes and were
33
34 succeeded by a headache?
35

36
37 Persons were classified as having migraine if they answered “yes” to question 1. The second
38
39 question was to determine whether they had MA or MO. MA was defined as subjects
40
41 answering “yes” to both questions and MO was defined as subjects answering “yes” to
42
43 question 1 and “no” to question 2. Subjects answering “no” to question 1 were considered
44
45 healthy. Any questionnaires containing blanks in these two questions were excluded for the
46
47 purpose of the present study. Validation of the screening questions showed that it was
48
49 possible to identify 76% of all subjects with migraine, 85% of all with MA and 72% of all
50
51 with MO. A detailed description of the validation of screening questions has been published
52
53 elsewhere.[18]
54
55
56
57
58
59
60

1
2
3 In the survey from 2002, participants who answered yes to question 1 were asked to specify
4 whether they had had migraine in the past year or not. This was not a part of the 1994 survey
5 therefore 1-year prevalence was only estimated in 2002. The 1-year prevalence rate was
6 calculated as the number of subjects reporting that they had had migraine in the past year
7 divided by the total number of subjects, and the lifetime prevalence rate as the number of
8 subjects reporting migraine in the past year or before that divided by the total number of
9 subjects. Because the age range of the 2 cohorts was different in 1994 and 2002, comparison
10 of the two prevalence rates was conducted only for twins aged 20 to 41. Comparison of the
11 two groups was performed with χ^2 test. The incidence cases were defined as subjects
12 reporting migraine in 2002 who did not report migraine in 1994. The average annual
13 incidence rate was estimated as per 1000 person years (PYs). Prevalence and incidence
14 estimates were stratified by sex, age and subtypes. Data analyses were performed with PASW
15 Statistics version 18.0 by SPSS Inc.

34 Results

36 *Participants*

37
38 Of all the subjects who returned the questionnaire in 1994, 97.1% (n=28,571) had answered
39 both migraine questions. More women (66.0%) had migraine than men (34.0%) whereas a
40 more even distribution of sex was seen in the group without migraine (49% women and 51%
41 men). The migraine group was older than the no-migraine group (men: median=30 vs. 27 and
42 mean=29 vs. 27; women: median=30 vs. 26 and mean=29 vs. 26).

43
44 In 2002, 91.2% (n=31,865) of all returned questionnaires were complete with regard to both
45 migraine questions. There were more women (69.6%) than men (30.4%) in the migraine
46 group whereas only little difference was found in the group without migraine (49% women
47 and 51% men). The median and mean age differed with one year between the migraine group

and the group without migraine (men: median and mean=45 vs. 44; women: median=43 vs. 42 and mean=44 vs. 43).

1-year prevalence

The 1-year prevalence in 2002 was 12.3%. Table 1 shows the sex-specific and subtype-specific prevalences. The age-specific 1-year prevalence of migraine, MA and MO is shown in figure 1A-C. The prevalence peaked around age 38 to 40 in both men and women. For MO the 1-year prevalence showed a plateau between ages 25 and 40 while for MA a sharp peak was seen around age 40.

Table 1. Sex-specific 1-year prevalence rates of migraine, migraine with aura (MA) and migraine without aura (MO) in 2002 (31,865 subjects aged 20 to 71).

2002	Migraine			MA			MO		
	Rate(%)	95% CI	n,crude	Rate(%)	95% CI	n,crude	Rate(%)	95% CI	n,crude
All subjects	12.3	11.9-12.7	3927	4.1	3.9-4.3	1307	8.2	7.9-8.5	2620
Women	16.5	15.9-17.2	2855	5.7	5.3-6.1	983	10.8	10.4-	1872
								11.3	
Men	7.3	6.9-7.8	1072	2.2	2.0-2.5	324	5.1	4.8-5.5	748

Lifetime prevalence

The lifetime prevalence was 16.1% in 1994 (age 12 to 41) and 25.2% in 2002 (age 20 to 71). The sex-specific and subtype-specific prevalence rates for both years are presented in table 2. In 1994 the age-specific lifetime prevalence of migraine in women peaked in the early thirties followed by a small decrease whereas the prevalence in men showed a plateau between age 27 to 41 (figure 2A-C). The prevalence of MO peaked around age 27 to 34 in women and 31 in men. The MA prevalence slowly increased with age. In 2002 the prevalence of migraine

peaked around age 40 and slowly decreased (figure 3A-C). For MO the prevalence increased to age 40 where it reached plateau. For MA the prevalence peaked around age 38.

Table 2. Sex-specific lifetime prevalence rates of migraine, migraine with aura (MA) and migraine without aura (MO) in 1994 (28,571 subjects aged 11 to 41) and 2002 (31,865 subjects aged 20 to 71).

	Migraine			MA			MO		
	Rate(%)	95% CI	n,crude	Rate(%)	95% CI	n,crude	Rate(%)	95% CI	n,crude
1994									
All subjects	16.1	15.6-16.6	4593	4.8	4.5-5.0	1368	11.3	10.9-11.7	3225
Women	20.5	19.8-21.3	3031	6.5	6.1-6.9	963	14.0	13.4-14.6	2068
Men	11.3	10.8-11.9	1562	2.9	2.7-3.2	405	8.4	7.9-8.9	1157
2002									
All subjects	25.2	24.7-25.8	8044	9.7	9.3-10.0	3086	15.6	15.1-16.0	4958
Women	32.4	31.6-33.3	5597	13.1	12.6-13.7	2265	19.3	18.7-20.0	3332
Men	16.8	16.1-17.4	2447	5.6	5.2-6.0	821	11.1	10.6-11.7	1626

Change in prevalence

In order to estimate possible changes in prevalence we compared the subjects aged 20 to 41 which comprised 22,053 persons in the 1994 cohort and 14810 persons in the 2002 cohort. The 2002 cohort was slightly older than the 1994 cohort (median=32 vs. 30, mean=31 vs. 30 and 90% percentiles 21 to 41 vs. 21 to 40). The lifetime prevalence for age 20 to 41 was increased from 1994 to 2002 (18.5% vs. 24.5%) by 32.2% (95% CI: 27.0 to 37.3%; $p<0.001$). The difference was primarily seen in the population older than 32 years (figure 4A-C). The increase was especially evident in MA (5.6% vs. 9.4%, $p<0.001$) but we also found a significant increase in MO as well (13.0% vs. 15.1%, $p<0.001$). The prevalence increased significantly in women from 24.0% to 30.9% and in men from 12.6% to 16.1%. The relative increase was similar for both sexes (27.8% vs. 28.8%).

Incidence

19,586 subjects had completed both twin surveys with regard to migraine. 16,442 subjects aged 12 to 41 did not report having migraine in 1994. Of those, 2,318 subjects reported migraine in 2002 resulting in an 8-year period incidence rate of 0.141 corresponding to an average annual incidence rate of migraine of 17.6 per 1000 person years (PYs). The incidence rates of migraine and its subtypes are listed in table 3. We did not find any significant difference in incidence between age groups 20-29 and 30-39 ($p=0.0834$) nor 30-39 and 40-49 ($p=0.0762$), however, a significantly higher incidence was found in the group aged 20-29 than 40-49 ($p=0.0007$). Decreasing incidence rate with age was especially seen in MO subjects. There were 2,206 subjects reported having MO in 1994 and who had also completed the 2002 survey. The average annual incidence rate of MA in these subjects was 25.8 PYs (95% CI: 23.5 to 28.3, $n_{crude}=456$).

Table 3. The sex-specific average annual incidence rates per 1000 person years (PYs) from 1994 to 2002 of migraine, migraine with aura (MA) and migraine without aura (MO) in 16,442 subjects aged 20 to 49.

	All subjects			Women			Men		
	1000PYs	95% CI	n,crude	1000PYs	95% CI	n,crude	1000PYs	95% CI	n,crude
Migraine	17.6	16.9-18.4	2,318	23.4	22.3-24.6	1,617	11.2	10.4-12.1	701
MA	5.6	5.2-6.1	741	8.0	7.4-8.7	553	3.0	2.6-3.5	188
MO	12.0	11.4-12.6	1,577	15.4	14.5-16.4	1,064	8.2	7.5-9.0	513

Discussion

The present study demonstrated a significant increase of self-reported migraine prevalence in the Danish young adult population from 1994 to 2002. The increase was especially evident in

1
2
3 MA and the increase in MO was also significant. The increase was primarily seen in the
4
5 population older than 32 years.
6
7

8 9 10 *Migraine lifetime prevalence*

11 The lifetime prevalence has been estimated in several population-based studies with large
12
13 variation between 11.2% and 27.5% in questionnaire-based studies and between 12% and
14
15 19% in interview-based studies in the developed countries.[3] The variation seen may be due
16
17 to difference in methodology. One might wonder why the prevalence of lifetime migraine in
18
19 2002 was unexpectedly high in our study compared to the lifetime prevalence in the other
20
21 developed countries. However, comparison of the prevalence found in other large-scale
22
23 comparable European population-based questionnaire studies our results were similar, for
24
25 references see.[4] This was true for both men and women. One explanation could be that
26
27 patients in Europe were more likely to receive a medical diagnosis than for example in the
28
29 US.[19] Very few studies have estimated the lifetime prevalence of migraine subtypes. A
30
31 previous Danish study.[20] showed a higher lifetime prevalence of MA than the one we
32
33 found in 1994 (6% vs. 4.8%). However, the prevalence of MO was lower than ours (8% vs.
34
35 11.3%). Another study found lower prevalence rates of both MA and MO, 3.3% and
36
37 7.1%.[21] We expected to see increasing lifetime prevalence with advancing age, however,
38
39 the prevalence was decreasing after the 5th decade. A decrease was especially seen in MA
40
41 whereas the prevalence in MO reached a plateau. This is likely due to recall bias as discussed
42
43 previously.[22-23] MA patients tend to neglect having migraine compared to MO because
44
45 MA attacks are less frequent and less severe.[24] That may explain the pronounced difference
46
47 in MA and MO patients.
48
49
50
51
52

53
54
55
56 *Is the migraine prevalence increasing?*
57
58
59
60

1
2
3 We found a 32% increase in the lifetime prevalence of migraine in a period of 8 years.
4
5 Change in lifetime as well as 1-year prevalence has previously been investigated in replicate
6
7 studies. A large-scale study investigating subjects aged 12 and up found that the lifetime
8
9 prevalence of migraine increased significantly by 16% over a period of 4 years in women
10
11 (10.1% vs. 11.7%, $p \leq 0.01$) but a non-significant decrease in men (4.3% vs. 3.8%).[6] The
12
13 group of 25 to 54 years which is more comparable with our study population also showed a
14
15 significant increase in women and a non-significant increase in men. Our study showed a
16
17 significant increase in both sexes. The difference seen may be due to different study
18
19 population or sample size. A Danish study investigating both lifetime and 1-year prevalence
20
21 of migraine from 1989 to 2001 found no significant changes, as only a tendency towards an
22
23 increase was observed (14.5% vs. 18.4%, difference -3.9, 95% CI: -11.5 to 3.8 for the
24
25 lifetime prevalence; 11.3% vs. 15.5%, difference -4.1, 95% CI: -11.1 to 2.8 for the 1-year
26
27 prevalence).[8] This increasing trend was also seen for 1-year prevalence in women (15.6%
28
29 vs. 23.5%, $p=0.14$). However, this study had a small sample size ($n=211$ and 207) and must
30
31 be interpreted with caution. A recent large-scale population-based study found a small
32
33 increase in the 1-year prevalence (12.1% vs. 13.2%, $p < 0.001$).[9] A marked increase in 6-
34
35 months prevalence over a period of 28 years (1.9% to 5.7%) was found in a study
36
37 investigating 7-year old children.[25] Other large-scale studies demonstrated no change in
38
39 migraine prevalence over time.[5,7] A true increase in prevalence would be attributed to
40
41 rising incidence. However, part of the increase may also be due to rising public awareness of
42
43 migraine or increased medical consultation resulting in an increased rate of physician
44
45 diagnosis.[26,27] We do not know of any approaches to increase awareness of migraine in
46
47 Denmark. However, an increase in medical consultation has been shown.[28] Subjects who
48
49 previously participated in the 1994 survey may be more aware of migraine since they already
50
51 have experienced similar questions. On balance our data convincingly show an increase in
52
53
54
55
56
57
58
59
60

1
2
3 prevalence but the size of the increase may not be as high as our finding of 32%. Due to the
4
5 short time span of 8 years, this must be caused by environmental factors and not by genes.
6
7 Mutations cannot increase the migraine prevalence so quickly in a general population.
8
9 Currently we do not know about any potential environmental factors or its nature or course.
10
11 Some factors such as social economic status,[5] smoking and alcohol,[29] have been
12
13 suggested based on cross-sectional studies but to our knowledge very few longitudinal studies
14
15 have investigated risk factors for migraine. One cohort study reported that smokers have a
16
17 higher risk of developing self-reported migraine.[30] Apparently, the need of more
18
19 longitudinal studies is wanted.
20
21
22
23
24

25 *Migraine 1-year prevalence*

26
27 Although our lifetime prevalence was high, the 1-year prevalence was found to match the
28
29 lower range of the prevalence rates in Europe based on large-scale comparable questionnaire
30
31 studies (11.6 to 16.3%, 7.5 to 9.5% in men and 15.6 to 25% in women) as well as in
32
33 interview-based studies.[4] Comparing the 1-year migraine prevalence in 2002 with the
34
35 lifetime prevalence in 2002, we found that more than 50% reporting lifetime migraine did not
36
37 experience attacks during the last year. This speaks for a favourable course of migraine. Only
38
39 few studies[24,27,31-34] have investigated the 1-year prevalence of migraine subtypes
40
41 showing a range for MA of 0.6% to 3.7% in men and 3.6% to 10.8% in women and for MO
42
43 2% to 7.3% and 7.5% to 11.9%, respectively. Our prevalence estimates were similar to those
44
45 found previously in Denmark and The United Kingdom.[24,33] The American Migraine
46
47 study revealed increasing prevalence in both male and female subjects from age 12 until
48
49 approximately age 40, after which a decreasing prevalence was noted.[35] This is in keeping
50
51 with our findings (see figure 1.A-C).
52
53
54
55
56
57
58
59
60

Incidence

A great variation is found in the literature for the incidence rate of migraine in the adult population (1.4 to 5.0 per 1000 PYs in men and 2.9 to 22 per 1000 PYs in women).[36-39]

Our incidence rate in women is in keeping with previous findings, however, the rate in men is somewhat higher. A previous small-scale study in Denmark found an incidence of 8.1 per 1000 PYs in 2001 in subjects aged 25 to 64.[40] We found an annual incidence rate of 17.6 per 1000 PYs for migraine. The difference seen could be due to different methodology or that our population was younger (20 to 49 years old).

Methodological considerations

It was possible in this study to differentiate between MA and MO because of the use of validated diagnostic questions.[18] Furthermore, it was possible to subdivide between men and women and to distinguish between age groups because of the large sample size.

However, the present study also has weaknesses. The validation of the two questions used to identify migraine cases showed that self-reported migraine was only correct in 74.5% of cases and furthermore approximately 23.8% of the migraine patients were not identified. Thus, our estimates would tend to be conservative. However, the sensitivity of our questions was higher than the sensitivity of an ICHD-II modified questionnaire[9] therefore our questions should be valid as a tool for identifying migraine and determining the prevalence and incidence.

Conclusions

Our most important finding was a substantial increase in the lifetime prevalence of migraine in Denmark from 1994 to 2002 confirming previous studies. Part of the increase may be due to increased medical consultation resulting in an increased rate of physician diagnosis or

1
2
3 awareness due to previously participation in the 1994 survey. It seems pertinent to study the
4
5 causes of the increase and to implement preventive measures.
6
7

8 9 **Acknowledgements**

10 We thank Secretary Jytte Duerlund for assistance in carrying out the “Twin Omnibus 2002”
11
12 study. She did not receive compensation for her assistance.
13
14

15 16 17 **Competing interest**

18 All authors declare that we have no significant competing financial, professional or personal
19
20 interests that might have influenced the performance or presentation of the work described in
21
22 this manuscript.
23
24
25
26
27

28 29 **Funding**

30 The project was funded by the Department of Neurology Research Fund, Glostrup Hospital.
31
32 The funding bodies had no role in the collection, analysis, and interpretation of data; in the
33
34 writing of the report; or in the decision to submit the article for publication.
35
36
37
38
39

40 41 **References**

- 42
43 1. Leonardi M, Steiner TJ, Scher AT, et al. The global burden of migraine: measuring
44
45 disability in headache disorders with WHO's Classification of Functioning, Disability
46
47 and Health (ICF). *J Headache Pain* 2005;**6**:429-40.
48
49 2. Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe
50
51 2010. *Eur Neuropsychopharmacol* 2011;**21**:718-79.
52
53 3. Stovner L, Hagen K, Jensen R, et al. The global burden of headache: a documentation
54
55 of headache prevalence and disability worldwide. *Cephalalgia* 2007;**27**:193-210.
56
57
58
59
60

- 1
2
3 4. Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight
4 project. *J Headache Pain* 2010;**11**:289-99.
- 5
6
7 5. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the
8 United States: data from the American Migraine Study II. *Headache* 2001;**41**:646-57.
- 9
10
11 6. Gilmour H, Wilkins K. Migraine. *Health Rep* 2001;**12**:23-40.
- 12
13
14 7. Henry P, Auray JP, Gaudin AF, et al. Prevalence and clinical characteristics of migraine
15 in France. *Neurology* 2002;**59**:232-7.
- 16
17
18 8. Lyngberg AC, Rasmussen BK, Jorgensen T, et al. Has the prevalence of migraine and
19 tension-type headache changed over a 12-year period? A Danish population survey. *Eur*
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
J Epidemiol 2005;**20**:243-9.
9. Linde M, Stovner LJ, Zwart JA, et al. Time trends in the prevalence of headache
disorders. The Nord-Trondelag Health Studies (HUNT 2 and HUNT 3). *Cephalalgia*
2011;**31**:585-96.
10. Skytthe A, Kyvik K, Holm NV, et al. The Danish Twin Registry: 127 birth cohorts of
twins. *Twin Res* 2002;**5**:352-7.
11. Skytthe A, Kyvik K, Bathum L, et al. The Danish Twin Registry in the new
millennium. *Twin Res Hum Genet* 2006;**9**:763-71.
12. Ulrich V, Gervil M, Fenger K, et al. The prevalence and characteristics of migraine in
twins from the general population. *Headache* 1999;**39**:173-80.
13. Kyvik KO, Christensen K, Skytthe A, et al. The Danish Twin Register. *Dan Med Bull*
1996;**43**:467-70.
14. Kyvik KO, Green A, Beck-Nielsen H. The new Danish Twin Register: establishment
and analysis of twinning rates. *Int J Epidemiol* 1995;**24**:589-96.
15. Christensen K, Vaupel JW, Holm NV, et al. Mortality among twins after age 6: fetal
origins hypothesis versus twin method. *BMJ* 1995;**310**:432-6.

16. Kyvik KO, Green A, Beck-Nielsen H. Concordance rates of insulin dependent diabetes mellitus: a population based study of young Danish twins. *BMJ* 1995;**311**:913-7.
17. Skadhauge LR, Christensen K, Kyvik KO, et al. Genetic and environmental influence on asthma: a population-based study of 11,688 Danish twin pairs. *Eur Respir J* 1999;**13**:8-14.
18. Le H, Tfelt-Hansen P, Russell MB, et al. Co-morbidity of migraine with somatic disease in a large population-based study. *Cephalalgia* 2011;**31**:43-64.
19. Lipton RB, Scher AI, Steiner TJ, et al. Patterns of health care utilization for migraine in England and in the United States. *Neurology* 2003;**60**:441-8.
20. Russell MB, Rasmussen BK, Thorvaldsen P, et al. Prevalence and sex-ratio of the subtypes of migraine. *Int J Epidemiol* 1995;**24**:612-8.
21. Svensson DA, Ekblom K, Larsson B, et al. Lifetime prevalence and characteristics of recurrent primary headaches in a population-based sample of Swedish twins. *Headache* 2002;**42**:754-65.
22. Bille B. A 40-year follow-up of school children with migraine. *Cephalalgia* 1997;**17**:488-91.
23. Rasmussen BK. Epidemiology of headache. *Cephalalgia* 1995;**15**:45-68.
24. Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. *Cephalalgia* 1992;**12**:221-8.
25. Sillanpaa M, Anttila P. Increasing prevalence of headache in 7-year-old schoolchildren. *Headache* 1996;**36**:466-70.
26. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. *Headache* 1998;**38**:87-96.
27. Lipton RB, Scher AI, Kolodner K, et al. Migraine in the United States: epidemiology and patterns of health care use. *Neurology* 2002;**58**:885-94.

- 1
2
3 28. Lyngberg AC, Rasmussen BK, Jorgensen T, et al. Secular changes in health care
4 utilization and work absence for migraine and tension-type headache: a population
5 based study. *Eur J Epidemiol* 2005;**20**:1007-14.
6
7
- 8
9 29. Aamodt AH, Stovner LJ, Hagen K, et al. Headache prevalence related to smoking and
10 alcohol use. The Head-HUNT Study. *Eur J Neurol* 2006;**13**:1233-8.
11
12
- 13 30. Hozawa A, Houston T, Steffes MW, et al. The association of cigarette smoking with
14 self-reported disease before middle age: the Coronary Artery Risk Development in
15 Young Adults (CARDIA) study. *Prev Med* 2006;**42**:193-9.
16
17
- 18 31. Lampl C, Buzath A, Baumhackl U, et al. One-year prevalence of migraine in Austria: a
19 nation-wide survey. *Cephalalgia* 2003;**23**:280-6.
20
21
- 22 32. Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. *Cephalalgia*
23 1997;**17**:15-22.
24
25
- 26 33. Steiner TJ, Scher AI, Stewart WF, et al. The prevalence and disability burden of adult
27 migraine in England and their relationships to age, gender and ethnicity. *Cephalalgia*
28 2003;**23**:519-27.
29
30
- 31 34. Zivadinov R, Willheim K, Jurjevic A, et al. Prevalence of migraine in Croatia: a
32 population-based survey. *Headache* 2001;**41**:805-12.
33
34
- 35 35. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the
36 United States. Relation to age, income, race, and other sociodemographic factors. *JAMA*
37 1992;**267**:64-9.
38
39
- 40 36. Becker C, Brobert GP, Almqvist PM, et al. Migraine incidence, comorbidity and health
41 resource utilization in the UK. *Cephalalgia* 2008;**28**:57-64.
42
43
- 44 37. Breslau N, Davis GC, Andreski P. Migraine, psychiatric disorders, and suicide
45 attempts: an epidemiologic study of young adults. *Psychiatry Res* 1991;**37**:11-23.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 38. Stang PE, Yanagihara PA, Swanson JW, et al. Incidence of migraine headache: a
4 population-based study in Olmsted County, Minnesota. *Neurology* 1992;**42**:1657-62.
5
6
7 39. Rozen TD, Swanson JW, Stang PE, et al. Increasing incidence of medically recognized
8 migraine headache in a United States population. *Neurology* 1999;**53**:1468-73.
9
10
11 40. Lyngberg AC, Rasmussen BK, Jorgensen T, et al. Incidence of primary headache: a
12 Danish epidemiologic follow-up study. *Am J Epidemiol* 2005;**161**:1066-73.
13
14
15
16
17
18
19

Figure legends


20
21 Figure 1A-C. The age- and sex-specific 1-year prevalence of migraine and its subtypes in
22 2002.
23
24
25

26
27
28 Figure 2A-C. The age- and sex-specific lifetime prevalence of migraine and its subtypes in
29 1994.
30
31
32

33
34
35 Figure 3A-C. The age- and sex-specific lifetime prevalence of migraine and its subtypes in
36 2002.
37
38
39

40
41
42 Figure 4A-C. Comparison of lifetime prevalence rates of 1994 with 2002 for subjects aged 20
43 to 41.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




A) Migraine, B) Migraine with aura and C) Migraine without aura

145x96mm (300 x 300 DPI)

Review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




A) Migraine, B) Migraine with aura and C) Migraine without aura

153x102mm (300 x 300 DPI)

Review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




A) Migraine, B) Migraine with aura and C) Migraine without aura

151x103mm (300 x 300 DPI)

view only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



A) Migraine, B) Migraine with aura and C) Migraine without aura

147x84mm (300 x 300 DPI)

review only



Increase in self-reported migraine prevalence in the Danish adult population: a prospective longitudinal population-based study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-000962.R1
Article Type:	Research
Date Submitted by the Author:	16-May-2012
Complete List of Authors:	Le, Han; Glostrup Hospital, Neurology, Danish Headache Center Tfelt-Hansen, Peer; Glostrup Hospital, Neurology, Danish Headache Center Skytthe, Axel; University of Southern Denmark, Epidemiology, Institute of Public Health, The Danish Twin Registry Kyvik, Kirsten; University of Southern Denmark, Institute of Regional Health Services Research; Odense University Hospital, Odense Patient data Explorative Network (OPEN) Olesen, Jes; Glostrup Hospital, Neurology, Danish Headache Center
Primary Subject Heading:	Neurology
Secondary Subject Heading:	Epidemiology
Keywords:	Migraine < NEUROLOGY, EPIDEMIOLOGY, Adult neurology < NEUROLOGY

SCHOLARONE™
Manuscripts

Only

Increase in self-reported migraine prevalence in the Danish adult population: a prospective longitudinal population-based study

Han Le¹, Peer Tfelt-Hansen¹, Axel Skytthe², Kirsten Ohm Kyvik^{3,4} and Jes Olesen¹

- 1) The Danish Headache Centre, Department of Neurology, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark.
- 2) The Danish Twin Registry, Epidemiology, Institute of Public Health, University of Southern Denmark, Odense, Denmark.
- 3) Institute of Regional Health Services Research, University of Southern Denmark, Odense, Denmark.
- 4) Odense Patient data Explorative Network (OPEN), Odense University Hospital, Odense, Denmark.

Corresponding author:

Jes Olesen, professor, DMSc

Danish Headache Center

Department of Neurology

Glostrup Hospital

DK-2600 Glostrup

Denmark

E-mail: jeol@regionh.dk

Phone: +45 38633036

Fax: +45 38633970

Keywords: migraine, epidemiology, prevalence, incidence, longitudinal study

Word count: 2702 (max 3000)

Abstract

Objective: It is uncertain whether migraine prevalence has increased in modern society. Our aim was to assess any change in migraine prevalence over an 8 year period among the adult population in Denmark. **Design:** Prospective longitudinal population-based study. **Setting:** 30,000 twin individuals were invited to participate in two cross-sectional questionnaire surveys containing validated questions to diagnose migraine in 1994 and 2002. The twins are representative of the Danish population with regard to migraine and other somatic diseases. **Participants:** The 1994 cohort comprised 28,571 twin individuals aged 12 to 41 and the 2002 cohort 31,865 twin individuals aged 20 to 71. **Outcome measures:** sex-specific, age-specific and subtype-specific incidence and lifetime prevalence as well as 1-year prevalence of migraine. **Results:** 1 year prevalence in 2002 was 12.3% for migraine, 4.1% for migraine with aura (MA) and 8.2% for migraine without aura (MO). Lifetime prevalence of migraine was 16.1% in 1994 (aged 12 to 41) and 25.2% in 2002 (aged 20 to 71). Lifetime prevalence of migraine for age 20 to 41 was increased from 1994 to 2002 (18.5% vs. 24.5%) by 32.2% (95% CI: 27.0 to 37.3%; $p < 0.001$). The difference was primarily seen in the population older than 32 years. The increase was especially evident in MA (5.6% vs. 9.4%, $p < 0.001$) but also a significant increase in MO was found (13.0% vs. 15.1%, $p < 0.001$). 8-year period incidence rate of migraine was 0.141 corresponding to an average annual incidence rate of 17.6 per 1000 person years. **Conclusions:** Lifetime prevalence of migraine in Denmark increased substantially from 1994 to 2002. Part of the increase may be due to increased medical consultation resulting in increased rate of physician diagnosis or awareness due to previously participation in the 1994 survey. It is pertinent to study the environmental causes of the increase and to implement preventive measures.

Word count of abstract: 300 (max 300)

1
2
3 **Article summary**
4

5 Article focus:
6

7 -Has migraine prevalence increased in modern society?
8
9

10
11
12 Key messages:
13

14 -Self-reported migraine prevalence increased substantially in the Danish young adult
15
16 population
17

18 -Sex-specific and age-specific prevalence and incidence of migraine and its subtypes was
19
20 estimated in a large population-based sample
21
22

23
24
25 Strengths and limitations:
26

27 -Large sample size made it possible to differentiate between MA and MO using the validated
28
29 diagnostic questions and furthermore subdivide between men and women and to distinguish
30
31 between age groups.
32

33
34 -The validation of the two questions used to identify migraine cases showed that self-reported
35
36 migraine was only correct in 74.5% of cases and furthermore approximately 23.8% of the
37
38 migraine patients were not identified. Thus, our estimates would tend to be conservative.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Migraine was in 2001 ranked by the World Health Organization as the 19th of disabling diseases[1] causing great societal costs. In 2010, the total societal cost in Europe was estimated to be € 18.5 billion per year for the 50 million migraine sufferers.[2] Migraine prevalence has been assessed in several large-scale population-based studies[3-4] but studies of incidence are sparse. It is uncertain whether migraine prevalence has increased in modern society. Replicate studies of migraine prevalence in the adult population using the same methodology at all evaluations showed conflicting results.[5-9] Furthermore, only few studies have distinguished between migraine with aura and migraine without aura.

“The Danish Twin Omnibus 1994 and 2002” were questionnaire studies among almost 30,000 and 35,000 twin individuals, respectively.[10-11] Both studies used the same validated questions to diagnose migraine and its subtypes. In the present publication the twin status is disregarded and the material is presented as a random sample from the Danish population, which is acceptable since these twins are representative of the whole Danish population with regard to migraine.[12]

The aim of our study was to estimate sex-specific, age-specific and subtype-specific incidence and lifetime prevalence as well as 1-year prevalence of migraine and to assess any change in migraine prevalence over an 8-year period among the young adult population in Denmark.

Material and methods

The study populations were based on twin cohorts enrolled in the Danish Twin Registry (DTR), one of the oldest and most complete population-based twin registries in the world.[10] The ascertainment of twins enrolled in this study was done using the Danish Civil Registration System as primary source. This system had since April 1st 1968 registered all

1
2
3 persons living in Denmark.[10-11,13] The twin cohorts from 1953 to 1982 were identified in
4
5 1991 by the mother assuming that a woman had twins if she gave birth to more than one child
6
7 within three consecutive days.[14] Identification of twins born between 1931 and 1952 was
8
9 based on an algorithm extracting all persons born on the same date, in the same parish and
10
11 with the same historical surname.[10] The DTR is validated and representative of the Danish
12
13 population as a whole.[12,15-17] The lifetime and 1-year prevalence of migraine did not
14
15 differ in monozygotic twins, dizygotic twins and single individuals.[12] The twins were
16
17 therefore regarded as single individuals in the present study.
18
19

20
21 The “Twin Omnibus 1994” comprised twin individuals from the cohorts 1953 to 1982 and
22
23 the “Twin Omnibus 2002” twin individuals from the cohorts 1931 to 1982. The
24
25 questionnaires investigated self-reported migraine identified based on the following
26
27 questions:
28

- 29 1. Have you ever had migraine?
- 30 2. Have you ever had visual disturbances that lasted from 5 to 60 minutes and were
31
32 succeeded by a headache?
33
34

35
36 Persons were classified as having migraine if they answered “yes” to question 1. The second
37
38 question was to determine whether they had MA or MO. MA was defined as subjects
39
40 answering “yes” to both questions and MO was defined as subjects answering “yes” to
41
42 question 1 and “no” to question 2. Subjects answering “no” to question 1 were considered
43
44 healthy. Any questionnaires containing blanks in these two questions were excluded for the
45
46 purpose of the present study. Validation of the screening questions showed that it was
47
48 possible to identify 76% of all subjects with migraine, 85% of all with MA and 72% of all
49
50 with MO. A detailed description of the validation of screening questions has been published
51
52 elsewhere.[18]
53
54
55
56
57
58
59
60

1
2
3 In the survey from 2002, participants who answered yes to question 1 were asked to specify
4 whether they had had migraine in the past year or not. This was not a part of the 1994 survey
5 therefore 1-year prevalence was only estimated in 2002. The 1-year prevalence rate was
6 calculated as the number of subjects reporting that they had had migraine in the past year
7 divided by the total number of subjects, and the lifetime prevalence rate as the number of
8 subjects reporting migraine in the past year or before that divided by the total number of
9 subjects. Because the age range of the 2 cohorts was different in 1994 and 2002, comparison
10 of the two prevalence rates was conducted only for twins aged 20 to 41. Comparison of the
11 two groups was performed with χ^2 test. The incidence cases were defined as subjects
12 reporting migraine in 2002 who did not report migraine in 1994. The average annual
13 incidence rate was estimated as per 1000 person years (PYs). Prevalence and incidence
14 estimates were stratified by sex, age and subtypes. Data analyses were performed with PASW
15 Statistics version 18.0 by SPSS Inc.

34 Results

36 *Participants*

37
38 Of all the subjects who returned the questionnaire in 1994, 97.1% (n=28,571) had answered
39 both migraine questions. More women (66.0%) had migraine than men (34.0%) whereas a
40 more even distribution of sex was seen in the group without migraine (49% women and 51%
41 men). The migraine group was older than the no-migraine group (men: median=30 vs. 27 and
42 mean=29 vs. 27; women: median=30 vs. 26 and mean=29 vs. 26).

43
44 In 2002, 91.2% (n=31,865) of all returned questionnaires were complete with regard to both
45 migraine questions. There were more women (69.6%) than men (30.4%) in the migraine
46 group whereas only little difference was found in the group without migraine (49% women
47 and 51% men). The median and mean age differed with one year between the migraine group
48
49
50
51
52
53
54
55
56
57
58
59
60

and the group without migraine (men: median and mean=45 vs. 44; women: median=43 vs. 42 and mean=44 vs. 43).

1-year prevalence

The 1-year prevalence in 2002 was 12.3%. Table 1 shows the sex-specific and subtype-specific prevalences. The age-specific 1-year prevalence of migraine, MA and MO is shown in figure 1A-C. The prevalence peaked around age 38 to 40 in both men and women. For MO the 1-year prevalence showed a plateau between ages 25 and 40 while for MA a sharp peak was seen around age 40.

Table 1. Sex-specific 1-year prevalence rates of migraine, migraine with aura (MA) and migraine without aura (MO) in 2002 (31,865 subjects aged 20 to 71).

	Migraine			MA			MO		
	Rate(%)	95% CI	n,crude	Rate(%)	95% CI	n,crude	Rate(%)	95% CI	n,crude
2002									
All subjects	12.3	11.9-12.7	3927	4.1	3.9-4.3	1307	8.2	7.9-8.5	2620
Women	16.5	15.9-17.2	2855	5.7	5.3-6.1	983	10.8	10.4-	1872
								11.3	
Men	7.3	6.9-7.8	1072	2.2	2.0-2.5	324	5.1	4.8-5.5	748

Lifetime prevalence

The lifetime prevalence was 16.1% in 1994 (age 12 to 41) and 25.2% in 2002 (age 20 to 71). The sex-specific and subtype-specific prevalence rates for both years are presented in table 2. In 1994 the age-specific lifetime prevalence of migraine in women peaked in the early thirties followed by a small decrease whereas the prevalence in men showed a plateau between age 27 to 41 (figure 2A-C). The prevalence of MO peaked around age 27 to 34 in women and 31 in men. The MA prevalence slowly increased with age. In 2002 the prevalence of migraine

peaked around age 40 and slowly decreased (figure 3A-C). For MO the prevalence increased to age 40 where it reached plateau. For MA the prevalence peaked around age 38.

Table 2. Sex-specific lifetime prevalence rates of migraine, migraine with aura (MA) and migraine without aura (MO) in 1994 (28,571 subjects aged 11 to 41) and 2002 (31,865 subjects aged 20 to 71).

	Migraine			MA			MO		
	Rate(%)	95% CI	n,crude	Rate(%)	95% CI	n,crude	Rate(%)	95% CI	n,crude
1994									
All subjects	16.1	15.6-16.6	4593	4.8	4.5-5.0	1368	11.3	10.9-11.7	3225
Women	20.5	19.8-21.3	3031	6.5	6.1-6.9	963	14.0	13.4-14.6	2068
Men	11.3	10.8-11.9	1562	2.9	2.7-3.2	405	8.4	7.9-8.9	1157
2002									
All subjects	25.2	24.7-25.8	8044	9.7	9.3-10.0	3086	15.6	15.1-16.0	4958
Women	32.4	31.6-33.3	5597	13.1	12.6-13.7	2265	19.3	18.7-20.0	3332
Men	16.8	16.1-17.4	2447	5.6	5.2-6.0	821	11.1	10.6-11.7	1626

Change in prevalence

In order to estimate possible changes in prevalence we compared the subjects aged 20 to 41 which comprised 22,053 persons in the 1994 cohort and 14810 persons in the 2002 cohort. The 2002 cohort was slightly older than the 1994 cohort (median=32 vs. 30, mean=31 vs. 30 and 90% percentiles 21 to 41 vs. 21 to 40). The lifetime prevalence for age 20 to 41 was increased from 1994 to 2002 (18.5% vs. 24.5%) by 32.2% (95% CI: 27.0 to 37.3%; $p<0.001$). The difference was primarily seen in the population older than 32 years (figure 4A-C). The increase was especially evident in MA (5.6% vs. 9.4%, $p<0.001$) but we also found a significant increase in MO as well (13.0% vs. 15.1%, $p<0.001$). The prevalence increased significantly in women from 24.0% to 30.9% and in men from 12.6% to 16.1%. The relative increase was similar for both sexes (27.8% vs. 28.8%).

Incidence

19,586 subjects had completed both twin surveys with regard to migraine. 16,442 subjects aged 12 to 41 did not report having migraine in 1994. Of those, 2,318 subjects reported migraine in 2002 resulting in an 8-year period incidence rate of 0.141 corresponding to an average annual incidence rate of migraine of 17.6 per 1000 person years (PYs). The incidence rates of migraine and its subtypes are listed in table 3. We did not find any significant difference in incidence between age groups 20-29 and 30-39 ($p=0.0834$) nor 30-39 and 40-49 ($p=0.0762$), however, a significantly higher incidence was found in the group aged 20-29 than 40-49 ($p=0.0007$). Decreasing incidence rate with age was especially seen in MO subjects. There were 2,206 subjects reported having MO in 1994 and who had also completed the 2002 survey. The average annual incidence rate of MA in these subjects was 25.8 PYs (95% CI: 23.5 to 28.3, $n_{crude}=456$).

Table 3. The sex-specific average annual incidence rates per 1000 person years (PYs) from 1994 to 2002 of migraine, migraine with aura (MA) and migraine without aura (MO) in 16,442 subjects aged 20 to 49.

	All subjects			Women			Men		
	1000PYs	95% CI	n,crude	1000PYs	95% CI	n,crude	1000PYs	95% CI	n,crude
Migraine	17.6	16.9-18.4	2,318	23.4	22.3-24.6	1,617	11.2	10.4-12.1	701
MA	5.6	5.2-6.1	741	8.0	7.4-8.7	553	3.0	2.6-3.5	188
MO	12.0	11.4-12.6	1,577	15.4	14.5-16.4	1,064	8.2	7.5-9.0	513

Discussion

The present study demonstrated a significant increase of self-reported migraine prevalence in the Danish young adult population from 1994 to 2002. The increase was especially evident in

1
2
3 MA and the increase in MO was also significant. The increase was primarily seen in the
4
5 population older than 32 years.
6
7

8 9 *Migraine lifetime prevalence*

10
11 The lifetime prevalence has been estimated in several population-based studies with large
12
13 variation between 11.2% and 27.5% in questionnaire-based studies and between 12% and
14
15 19% in interview-based studies in the developed countries.[3] The variation seen may be due
16
17 to difference in methodology. One might wonder why the prevalence of lifetime migraine in
18
19 2002 was unexpectedly high in our study compared to the lifetime prevalence in the other
20
21 developed countries. However, comparison of the prevalence found in other large-scale
22
23 comparable European population-based questionnaire studies our results were similar, for
24
25 references see.[4] This was true for both men and women. One explanation could be that
26
27 patients in Europe were more likely to receive a medical diagnosis than for example in the
28
29 US.[19] Very few studies have estimated the lifetime prevalence of migraine subtypes. A
30
31 previous Danish study.[20] showed a higher lifetime prevalence of MA than the one we
32
33 found in 1994 (6% vs. 4.8%). However, the prevalence of MO was lower than ours (8% vs.
34
35 11.3%). Another study found lower prevalence rates of both MA and MO, 3.3% and
36
37 7.1%.[21] We expected to see increasing lifetime prevalence with advancing age, however,
38
39 the prevalence was decreasing after the 5th decade. A decrease was especially seen in MA
40
41 whereas the prevalence in MO reached a plateau. This is likely due to recall bias as discussed
42
43 previously.[22-23] MA patients tend to neglect having migraine compared to MO because
44
45 MA attacks are less frequent and less severe.[24] That may explain the pronounced difference
46
47 in MA and MO patients.
48
49
50
51
52

53
54
55
56 *Is the migraine prevalence increasing?*
57
58
59
60

1
2
3 We found a 32% increase in the lifetime prevalence of migraine in a period of 8 years.
4
5 Change in lifetime as well as 1-year prevalence has previously been investigated in replicate
6
7 studies. A large-scale study investigating subjects aged 12 and up found that the lifetime
8
9 prevalence of migraine increased significantly by 16% over a period of 4 years in women
10
11 (10.1% vs. 11.7%, $p \leq 0.01$) but a non-significant decrease was seen in men (4.3% vs. 3.8%).[6]
12
13
14 The group of 25 to 54 years which is more comparable with our study population also
15
16 showed a significant increase in women and a non-significant increase in men. Our study
17
18 showed a significant increase in both sexes. The difference seen may be due to different study
19
20 population or sample size. A Danish study investigating both lifetime and 1-year prevalence
21
22 of migraine from 1989 to 2001 found no significant changes, as only a tendency towards an
23
24 increase was observed (14.5% vs. 18.4%, difference -3.9, 95% CI: -11.5 to 3.8 for the
25
26 lifetime prevalence; 11.3% vs. 15.5%, difference -4.1, 95% CI: -11.1 to 2.8 for the 1-year
27
28 prevalence).[8] This increasing trend was also seen for 1-year prevalence in women (15.6%
29
30 vs. 23.5%, $p=0.14$). However, this study had a small sample size ($n=211$ and 207) and must
31
32 be interpreted with caution. A recent large-scale population-based study found a small
33
34 increase in the 1-year prevalence (12.1% vs. 13.2%, $p < 0.001$).[9] A marked increase in 6-
35
36 months prevalence over a period of 28 years (1.9% to 5.7%) was found in a study
37
38 investigating 7-year old children.[25] Other large-scale studies demonstrated no change in
39
40 migraine prevalence over time.[5,7] A true increase in prevalence would be attributed to
41
42 rising incidence. However, part of the increase may also be due to rising public awareness of
43
44 migraine or increased medical consultation resulting in an increased rate of physician
45
46 diagnosis.[26,27] We do not know of any approaches to increase awareness of migraine in
47
48 Denmark. However, an increase in medical consultation has been shown.[28] Subjects born
49
50 in 1953-82 were invited to participate in both surveys. This means that the group of subjects
51
52 who did participate in both surveys would have experienced the migraine questions already.
53
54
55
56
57
58
59
60

1
2
3 It is possible that these subjects became more aware of migraine to the second survey. On
4
5 balance our data convincingly show an increase in prevalence but the size of the increase may
6
7 not be as high as our finding of 32%. Due to the short time span of 8 years, this must be
8
9 caused by environmental factors and not by genes. Mutations cannot increase the migraine
10
11 prevalence so quickly in a general population. Currently we do not know about any potential
12
13 environmental factors or its nature or course. Some factors such as social economic status,[5]
14
15 smoking and alcohol,[29] have been suggested based on cross-sectional studies but to our
16
17 knowledge very few longitudinal studies have investigated risk factors for migraine. One
18
19 cohort study reported that smokers have a higher risk of developing self-reported
20
21 migraine.[30] Apparently, the need of more longitudinal studies is wanted.
22
23
24
25
26

27 *Migraine 1-year prevalence*

28
29 Although our lifetime prevalence was high, the 1-year prevalence was found to match the
30
31 lower range of the prevalence rates in Europe based on large-scale comparable questionnaire
32
33 studies (11.6 to 16.3%, 7.5 to 9.5% in men and 15.6 to 25% in women) as well as in
34
35 interview-based studies.[4] Comparing the 1-year migraine prevalence in 2002 with the
36
37 lifetime prevalence in 2002, we found that more than 50% reporting lifetime migraine did not
38
39 experience attacks during the last year. This speaks for a favourable course of migraine. Only
40
41 few studies[24,27,31-34] have investigated the 1-year prevalence of migraine subtypes
42
43 showing a range for MA of 0.6% to 3.7% in men and 3.6% to 10.8% in women and for MO
44
45 2% to 7.3% and 7.5% to 11.9%, respectively. Our prevalence estimates were similar to those
46
47 found previously in Denmark and The United Kingdom.[24,33] The American Migraine
48
49 study revealed increasing prevalence in both male and female subjects from age 12 until
50
51 approximately age 40, after which a decreasing prevalence was noted.[35] This is in keeping
52
53 with our findings (see figure 1.A-C).
54
55
56
57
58
59
60

Incidence

A great variation is found in the literature for the incidence rate of migraine in the adult population (1.4 to 5.0 per 1000 PYs in men and 2.9 to 22 per 1000 PYs in women).[36-39] Our incidence rate in women is in keeping with previous findings, however, the rate in men is somewhat higher. A previous small-scale study in Denmark found an incidence of 8.1 per 1000 PYs in 2001 in subjects aged 25 to 64.[40] We found an annual incidence rate of 17.6 per 1000 PYs for migraine. The difference seen could be due to different methodology or that our population was younger (20 to 49 years old).

Methodological considerations

It was possible in this study to differentiate between MA and MO because of the use of validated diagnostic questions.[18] Furthermore, it was possible to subdivide between men and women and to distinguish between age groups because of the large sample size. However, the present study also has weaknesses. The validation of the two questions used to identify migraine cases showed that self-reported migraine was only correct in 74.5% of cases and furthermore approximately 23.8% of the migraine patients were not identified. Thus, our estimates would tend to be conservative. However, the sensitivity of our questions was higher than the sensitivity of an ICHD-II modified questionnaire[9] therefore our questions should be valid as a tool for identifying migraine and determining the prevalence and incidence.

Conclusions

Our most important finding was a substantial increase in the lifetime prevalence of self-reported migraine in Denmark from 1994 to 2002 confirming previous studies. Part of

1
2
3 the increase may be due to increased medical consultation resulting in an increased rate of
4 physician diagnosis or awareness due to previous participation in the 1994 survey. It seems
5 pertinent to study the causes of the increase and to implement preventive measures.
6
7
8
9

10 11 12 **Acknowledgements**

13
14 We thank Secretary Jytte Duerlund for her assistance in carrying out the “Twin Omnibus
15 2002” study. She did not receive compensation for her assistance.
16
17
18
19

20 21 **Competing interest**

22 All authors declare that we have no significant competing financial, professional or personal
23 interests that might have influenced the performance or presentation of the work described in
24 this manuscript.
25
26
27
28
29

30 31 32 **Exclusive license statement**

33 The Corresponding Author has the right to grant on behalf of all authors and does grant on
34 behalf of all authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group
35 Ltd and its Licensees to permit this article to be published in BMJ Open and any other
36 BMJ PGL products to exploit all subsidiary rights, as set out in our licence
37 (http://group.bmj.com/products/journals/instructions-for-authors/wholly_owned_licence.pdf)
38 and the Corresponding Author accepts and understands that any supply made under these
39 terms is made by BMJ PGL to the Corresponding Author.
40
41
42
43
44
45
46
47
48
49

50 51 52 **Research ethics**

53 This study was a registry study based solely on questionnaires and did not require any
54 approval from the Ethics Committee according to national regulations.
55
56
57
58
59
60

Funding

The project was funded by the Department of Neurology Research Fund, Glostrup Hospital (grant number not applicable). The funding bodies had no role in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

References

1. Leonardi M, Steiner TJ, Scher AT, et al. The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). *J Headache Pain* 2005;**6**:429-40.
2. Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. *Eur Neuropsychopharmacol* 2011;**21**:718-79.
3. Stovner L, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. *Cephalalgia* 2007;**27**:193-210.
4. Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. *J Headache Pain* 2010;**11**:289-99.
5. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. *Headache* 2001;**41**:646-57.
6. Gilmour H, Wilkins K. Migraine. *Health Rep* 2001;**12**:23-40.
7. Henry P, Auray JP, Gaudin AF, et al. Prevalence and clinical characteristics of migraine in France. *Neurology* 2002;**59**:232-7.
8. Lyngberg AC, Rasmussen BK, Jorgensen T, et al. Has the prevalence of migraine and tension-type headache changed over a 12-year period? A Danish population survey. *Eur J Epidemiol* 2005;**20**:243-9.

- 1
2
3 9. Linde M, Stovner LJ, Zwart JA, et al. Time trends in the prevalence of headache
4 disorders. The Nord-Trondelag Health Studies (HUNT 2 and HUNT 3). *Cephalalgia*
5 2011;**31**:585-96.
6
7
- 8
9
10 10. Skytthe A, Kyvik K, Holm NV, et al. The Danish Twin Registry: 127 birth cohorts of
11 twins. *Twin Res* 2002;**5**:352-7.
12
- 13
14 11. Skytthe A, Kyvik K, Bathum L, et al. The Danish Twin Registry in the new
15 millennium. *Twin Res Hum Genet* 2006;**9**:763-71.
16
- 17
18 12. Ulrich V, Gervil M, Fenger K, et al. The prevalence and characteristics of migraine in
19 twins from the general population. *Headache* 1999;**39**:173-80.
20
- 21
22 13. Kyvik KO, Christensen K, Skytthe A, et al. The Danish Twin Register. *Dan Med Bull*
23 1996;**43**:467-70.
24
- 25
26 14. Kyvik KO, Green A, Beck-Nielsen H. The new Danish Twin Register: establishment
27 and analysis of twinning rates. *Int J Epidemiol* 1995;**24**:589-96.
28
- 29
30 15. Christensen K, Vaupel JW, Holm NV, et al. Mortality among twins after age 6: fetal
31 origins hypothesis versus twin method. *BMJ* 1995;**310**:432-6.
32
- 33
34 16. Kyvik KO, Green A, Beck-Nielsen H. Concordance rates of insulin dependent diabetes
35 mellitus: a population based study of young Danish twins. *BMJ* 1995;**311**:913-7.
36
- 37
38 17. Skadhauge LR, Christensen K, Kyvik KO, et al. Genetic and environmental influence
39 on asthma: a population-based study of 11,688 Danish twin pairs. *Eur Respir J*
40 1999;**13**:8-14.
41
- 42
43 18. Le H, Tfelt-Hansen P, Russell MB, et al. Co-morbidity of migraine with somatic
44 disease in a large population-based study. *Cephalalgia* 2011;**31**:43-64.
45
- 46
47 19. Lipton RB, Scher AI, Steiner TJ, et al. Patterns of health care utilization for migraine in
48 England and in the United States. *Neurology* 2003;**60**:441-8.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
- 2
- 3 20. Russell MB, Rasmussen BK, Thorvaldsen P, et al. Prevalence and sex-ratio of the
- 4 subtypes of migraine. *Int J Epidemiol* 1995;**24**:612-8.
- 5
- 6
- 7 21. Svensson DA, Ekblom K, Larsson B, et al. Lifetime prevalence and characteristics of
- 8 recurrent primary headaches in a population-based sample of Swedish twins. *Headache*
- 9 2002;**42**:754-65.
- 10
- 11
- 12
- 13 22. Bille B. A 40-year follow-up of school children with migraine. *Cephalalgia*
- 14 1997;**17**:488-91.
- 15
- 16
- 17 23. Rasmussen BK. Epidemiology of headache. *Cephalalgia* 1995;**15**:45-68.
- 18
- 19
- 20 24. Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an
- 21 epidemiological study. *Cephalalgia* 1992;**12**:221-8.
- 22
- 23
- 24 25. Sillanpaa M, Anttila P. Increasing prevalence of headache in 7-year-old schoolchildren.
- 25 *Headache* 1996;**36**:466-70.
- 26
- 27
- 28 26. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the
- 29 American Migraine Study. *Headache* 1998;**38**:87-96.
- 30
- 31
- 32 27. Lipton RB, Scher AI, Kolodner K, et al. Migraine in the United States: epidemiology
- 33 and patterns of health care use. *Neurology* 2002;**58**:885-94.
- 34
- 35
- 36 28. Lyngberg AC, Rasmussen BK, Jorgensen T, et al. Secular changes in health care
- 37 utilization and work absence for migraine and tension-type headache: a population
- 38 based study. *Eur J Epidemiol* 2005;**20**:1007-14.
- 39
- 40
- 41 29. Aamodt AH, Stovner LJ, Hagen K, et al. Headache prevalence related to smoking and
- 42 alcohol use. The Head-HUNT Study. *Eur J Neurol* 2006;**13**:1233-8.
- 43
- 44
- 45 30. Hozawa A, Houston T, Steffes MW, et al. The association of cigarette smoking with
- 46 self-reported disease before middle age: the Coronary Artery Risk Development in
- 47 Young Adults (CARDIA) study. *Prev Med* 2006;**42**:193-9.
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 31. Lampl C, Buzath A, Baumhackl U, et al. One-year prevalence of migraine in Austria: a
4
5 nation-wide survey. *Cephalalgia* 2003;**23**:280-6.
6
- 7
8 32. Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. *Cephalalgia*
9
10 1997;**17**:15-22.
- 11
12 33. Steiner TJ, Scher AI, Stewart WF, et al. The prevalence and disability burden of adult
13
14 migraine in England and their relationships to age, gender and ethnicity. *Cephalalgia*
15
16 2003;**23**:519-27.
17
- 18
19 34. Zivadinov R, Willheim K, Jurjevic A, et al. Prevalence of migraine in Croatia: a
20
21 population-based survey. *Headache* 2001;**41**:805-12.
22
- 23
24 35. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the
25
26 United States. Relation to age, income, race, and other sociodemographic factors. *JAMA*
27
28 1992;**267**:64-9.
- 29
30 36. Becker C, Brobert GP, Almqvist PM, et al. Migraine incidence, comorbidity and health
31
32 resource utilization in the UK. *Cephalalgia* 2008;**28**:57-64.
33
- 34
35 37. Breslau N, Davis GC, Andreski P. Migraine, psychiatric disorders, and suicide
36
37 attempts: an epidemiologic study of young adults. *Psychiatry Res* 1991;**37**:11-23.
38
- 39
40 38. Stang PE, Yanagihara PA, Swanson JW, et al. Incidence of migraine headache: a
41
42 population-based study in Olmsted County, Minnesota. *Neurology* 1992;**42**:1657-62.
- 43
44 39. Rozen TD, Swanson JW, Stang PE, et al. Increasing incidence of medically recognized
45
46 migraine headache in a United States population. *Neurology* 1999;**53**:1468-73.
- 47
48 40. Lyngberg AC, Rasmussen BK, Jorgensen T, et al. Incidence of primary headache: a
49
50 Danish epidemiologic follow-up study. *Am J Epidemiol* 2005;**161**:1066-73.
51

52 53 54 55 **Figure legends**


1
2
3 Figure 1A-C. The age- and sex-specific 1-year prevalence of migraine and its subtypes in
4
5 2002.
6
7

8
9
10 Figure 2A-C. The age- and sex-specific lifetime prevalence of migraine and its subtypes in
11
12 1994.
13

14
15
16 Figure 3A-C. The age- and sex-specific lifetime prevalence of migraine and its subtypes in
17
18 2002.
19

20
21
22
23 Figure 4A-C. Comparison of lifetime prevalence rates of 1994 with 2002 for subjects aged 20
24 to 41.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




A) Migraine, B) Migraine with aura and C) Migraine without aura

145x96mm (300 x 300 DPI)

Review only


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



A) Migraine, B) Migraine with aura and C) Migraine without aura

153x102mm (300 x 300 DPI)


Review only



A) Migraine, B) Migraine with aura and C) Migraine without aura

151x103mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



A) Migraine, B) Migraine with aura and C) Migraine without aura

147x84mm (300 x 300 DPI)

review only

Increase in self-reported migraine prevalence in the Danish adult population: a prospective longitudinal population-based study

Han Le¹, Peer Tfelt-Hansen¹, Axel Skytthe², Kirsten Ohm Kyvik^{3,4} and Jes Olesen¹

- 1) The Danish Headache Centre, Department of Neurology, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark.
- 2) The Danish Twin Registry, Epidemiology, Institute of Public Health, University of Southern Denmark, Odense, Denmark.
- 3) Institute of Regional Health Services Research, University of Southern Denmark, Odense, Denmark.
- 4) Odense Patient data Explorative Network (OPEN), Odense University Hospital, Odense, Denmark.

Corresponding author:

Jes Olesen, professor, DMSc

Danish Headache Center

Department of Neurology

Glostrup Hospital

DK-2600 Glostrup

Denmark

E-mail: jeol@regionh.dk

Phone: +45 38633036

Fax: +45 38633970

Keywords: migraine, epidemiology, prevalence, incidence, longitudinal study

Word count: 2702 (max 3000)

Abstract

Objective: It is uncertain whether migraine prevalence has increased in modern society. Our aim was to assess any change in migraine prevalence over an 8 year period among the adult population in Denmark. **Design:** Prospective longitudinal population-based study. **Setting:** 30,000 twin individuals were invited to participate in two cross-sectional questionnaire surveys containing validated questions to diagnose migraine in 1994 and 2002. The twins are representative of the Danish population with regard to migraine and other somatic diseases. **Participants:** The 1994 cohort comprised 28,571 twin individuals aged 12 to 41 and the 2002 cohort 31,865 twin individuals aged 20 to 71. **Outcome measures:** sex-specific, age-specific and subtype-specific incidence and lifetime prevalence as well as 1-year prevalence of migraine. **Results:** 1 year prevalence in 2002 was 12.3% for migraine, 4.1% for migraine with aura (MA) and 8.2% for migraine without aura (MO). Lifetime prevalence of migraine was 16.1% in 1994 (aged 12 to 41) and 25.2% in 2002 (aged 20 to 71). Lifetime prevalence of migraine for age 20 to 41 was increased from 1994 to 2002 (18.5% vs. 24.5%) by 32.2% (95% CI: 27.0 to 37.3%; $p < 0.001$). The difference was primarily seen in the population older than 32 years. The increase was especially evident in MA (5.6% vs. 9.4%, $p < 0.001$) but also a significant increase in MO was found (13.0% vs. 15.1%, $p < 0.001$). 8-year period incidence rate of migraine was 0.141 corresponding to an average annual incidence rate of 17.6 per 1000 person years. **Conclusions:** Lifetime prevalence of migraine in Denmark increased substantially from 1994 to 2002. Part of the increase may be due to increased medical consultation resulting in increased rate of physician diagnosis or awareness due to previously participation in the 1994 survey. It is pertinent to study the environmental causes of the increase and to implement preventive measures.

Word count of abstract: 300 (max 300)

Article summary

Article focus:

-Has migraine prevalence increased in modern society?

Key messages:

-Self-reported migraine prevalence increased substantially in the Danish young adult population

-Sex-specific and age-specific prevalence and incidence of migraine and its subtypes was estimated in a large population-based sample

Strengths and limitations:

-Large sample size made it possible to differentiate between MA and MO using the validated diagnostic questions and furthermore subdivide between men and women and to distinguish between age groups.

-The validation of the two questions used to identify migraine cases showed that self-reported migraine was only correct in 74.5% of cases and furthermore approximately 23.8% of the migraine patients were not identified. Thus, our estimates would tend to be conservative.

Introduction

Migraine was in 2001 ranked by the World Health Organization as the 19th of disabling diseases[1] causing great societal costs. In 2010, the total societal cost in Europe was estimated to be € 18.5 billion per year for the 50 million migraine sufferers.[2] Migraine prevalence has been assessed in several large-scale population-based studies[3-4] but studies of incidence are sparse. It is uncertain whether migraine prevalence has increased in modern society. Replicate studies of migraine prevalence in the adult population using the same methodology at all evaluations showed conflicting results.[5-9] Furthermore, only few studies have distinguished between migraine with aura and migraine without aura.

“The Danish Twin Omnibus 1994 and 2002” were questionnaire studies among almost 30,000 and 35,000 twin individuals, respectively.[10-11] Both studies used the same validated questions to diagnose migraine and its subtypes. In the present publication the twin status is disregarded and the material is presented as a random sample from the Danish population, which is acceptable since these twins are representative of the whole Danish population with regard to migraine.[12]

The aim of our study was to estimate sex-specific, age-specific and subtype-specific incidence and lifetime prevalence as well as 1-year prevalence of migraine and to assess any change in migraine prevalence over an 8-year period among the young adult population in Denmark.

Material and methods

The study populations were based on twin cohorts enrolled in the Danish Twin Registry (DTR), one of the oldest and most complete population-based twin registries in the world.[10] The ascertainment of twins enrolled in this study was done using the Danish Civil Registration System as primary source. This system had since April 1st 1968 registered all

1
2
3 persons living in Denmark.[10-11,13] The twin cohorts from 1953 to 1982 were identified in
4
5 1991 by the mother assuming that a woman had twins if she gave birth to more than one child
6
7 within three consecutive days.[14] Identification of twins born between 1931 and 1952 was
8
9 based on an algorithm extracting all persons born on the same date, in the same parish and
10
11 with the same historical surname.[10] The DTR is validated and representative of the Danish
12
13 population as a whole.[12,15-17] The lifetime and 1-year prevalence of migraine did not
14
15 differ in monozygotic twins, dizygotic twins and single individuals.[12] The twins were
16
17 therefore regarded as single individuals in the present study.
18
19

20
21 The “Twin Omnibus 1994” comprised twin individuals from the cohorts 1953 to 1982 and
22
23 the “Twin Omnibus 2002” twin individuals from the cohorts 1931 to 1982. The
24
25 questionnaires investigated self-reported migraine identified based on the following
26
27 questions:
28

- 29 1. Have you ever had migraine?
- 30 2. Have you ever had visual disturbances that lasted from 5 to 60 minutes and were
31
32 succeeded by a headache?
33
34

35
36 Persons were classified as having migraine if they answered “yes” to question 1. The second
37
38 question was to determine whether they had MA or MO. MA was defined as subjects
39
40 answering “yes” to both questions and MO was defined as subjects answering “yes” to
41
42 question 1 and “no” to question 2. Subjects answering “no” to question 1 were considered
43
44 healthy. Any questionnaires containing blanks in these two questions were excluded for the
45
46 purpose of the present study. Validation of the screening questions showed that it was
47
48 possible to identify 76% of all subjects with migraine, 85% of all with MA and 72% of all
49
50 with MO. A detailed description of the validation of screening questions has been published
51
52 elsewhere.[18]
53
54
55
56
57
58
59
60

1
2
3 In the survey from 2002, participants who answered yes to question 1 were asked to specify
4 whether they had had migraine in the past year or not. This was not a part of the 1994 survey
5 therefore 1-year prevalence was only estimated in 2002. The 1-year prevalence rate was
6 calculated as the number of subjects reporting that they had had migraine in the past year
7 divided by the total number of subjects, and the lifetime prevalence rate as the number of
8 subjects reporting migraine in the past year or before that divided by the total number of
9 subjects. Because the age range of the 2 cohorts was different in 1994 and 2002, comparison
10 of the two prevalence rates was conducted only for twins aged 20 to 41. Comparison of the
11 two groups was performed with χ^2 test. The incidence cases were defined as subjects
12 reporting migraine in 2002 who did not report migraine in 1994. The average annual
13 incidence rate was estimated as per 1000 person years (PYs). Prevalence and incidence
14 estimates were stratified by sex, age and subtypes. Data analyses were performed with PASW
15 Statistics version 18.0 by SPSS Inc.

34 Results

36 *Participants*

37 Of all the subjects who returned the questionnaire in 1994, 97.1% (n=28,571) had answered
38 both migraine questions. More women (66.0%) had migraine than men (34.0%) whereas a
39 more even distribution of sex was seen in the group without migraine (49% women and 51%
40 men). The migraine group was older than the no-migraine group (men: median=30 vs. 27 and
41 mean=29 vs. 27; women: median=30 vs. 26 and mean=29 vs. 26).

42 In 2002, 91.2% (n=31,865) of all returned questionnaires were complete with regard to both
43 migraine questions. There were more women (69.6%) than men (30.4%) in the migraine
44 group whereas only little difference was found in the group without migraine (49% women
45 and 51% men). The median and mean age differed with one year between the migraine group
46 and 51% men).

and the group without migraine (men: median and mean=45 vs. 44; women: median=43 vs. 42 and mean=44 vs. 43).

1-year prevalence

The 1-year prevalence in 2002 was 12.3%. Table 1 shows the sex-specific and subtype-specific prevalences. The age-specific 1-year prevalence of migraine, MA and MO is shown in figure 1A-C. The prevalence peaked around age 38 to 40 in both men and women. For MO the 1-year prevalence showed a plateau between ages 25 and 40 while for MA a sharp peak was seen around age 40.

Table 1. Sex-specific 1-year prevalence rates of migraine, migraine with aura (MA) and migraine without aura (MO) in 2002 (31,865 subjects aged 20 to 71).

2002	Migraine			MA			MO		
	Rate(%)	95% CI	n,crude	Rate(%)	95% CI	n,crude	Rate(%)	95% CI	n,crude
All subjects	12.3	11.9-12.7	3927	4.1	3.9-4.3	1307	8.2	7.9-8.5	2620
Women	16.5	15.9-17.2	2855	5.7	5.3-6.1	983	10.8	10.4-	1872
								11.3	
Men	7.3	6.9-7.8	1072	2.2	2.0-2.5	324	5.1	4.8-5.5	748

Lifetime prevalence

The lifetime prevalence was 16.1% in 1994 (age 12 to 41) and 25.2% in 2002 (age 20 to 71). The sex-specific and subtype-specific prevalence rates for both years are presented in table 2. In 1994 the age-specific lifetime prevalence of migraine in women peaked in the early thirties followed by a small decrease whereas the prevalence in men showed a plateau between age 27 to 41 (figure 2A-C). The prevalence of MO peaked around age 27 to 34 in women and 31 in men. The MA prevalence slowly increased with age. In 2002 the prevalence of migraine

peaked around age 40 and slowly decreased (figure 3A-C). For MO the prevalence increased to age 40 where it reached plateau. For MA the prevalence peaked around age 38.

Table 2. Sex-specific lifetime prevalence rates of migraine, migraine with aura (MA) and migraine without aura (MO) in 1994 (28,571 subjects aged 11 to 41) and 2002 (31,865 subjects aged 20 to 71).

	Migraine			MA			MO		
	Rate(%)	95% CI	n,crude	Rate(%)	95% CI	n,crude	Rate(%)	95% CI	n,crude
1994									
All subjects	16.1	15.6-16.6	4593	4.8	4.5-5.0	1368	11.3	10.9-11.7	3225
Women	20.5	19.8-21.3	3031	6.5	6.1-6.9	963	14.0	13.4-14.6	2068
Men	11.3	10.8-11.9	1562	2.9	2.7-3.2	405	8.4	7.9-8.9	1157
2002									
All subjects	25.2	24.7-25.8	8044	9.7	9.3-10.0	3086	15.6	15.1-16.0	4958
Women	32.4	31.6-33.3	5597	13.1	12.6-13.7	2265	19.3	18.7-20.0	3332
Men	16.8	16.1-17.4	2447	5.6	5.2-6.0	821	11.1	10.6-11.7	1626

Change in prevalence

In order to estimate possible changes in prevalence we compared the subjects aged 20 to 41 which comprised 22,053 persons in the 1994 cohort and 14810 persons in the 2002 cohort. The 2002 cohort was slightly older than the 1994 cohort (median=32 vs. 30, mean=31 vs. 30 and 90% percentiles 21 to 41 vs. 21 to 40). The lifetime prevalence for age 20 to 41 was increased from 1994 to 2002 (18.5% vs. 24.5%) by 32.2% (95% CI: 27.0 to 37.3%; $p<0.001$). The difference was primarily seen in the population older than 32 years (figure 4A-C). The increase was especially evident in MA (5.6% vs. 9.4%, $p<0.001$) but we also found a significant increase in MO as well (13.0% vs. 15.1%, $p<0.001$). The prevalence increased significantly in women from 24.0% to 30.9% and in men from 12.6% to 16.1%. The relative increase was similar for both sexes (27.8% vs. 28.8%).

Incidence

19,586 subjects had completed both twin surveys with regard to migraine. 16,442 subjects aged 12 to 41 did not report having migraine in 1994. Of those, 2,318 subjects reported migraine in 2002 resulting in an 8-year period incidence rate of 0.141 corresponding to an average annual incidence rate of migraine of 17.6 per 1000 person years (PYs). The incidence rates of migraine and its subtypes are listed in table 3. We did not find any significant difference in incidence between age groups 20-29 and 30-39 ($p=0.0834$) nor 30-39 and 40-49 ($p=0.0762$), however, a significantly higher incidence was found in the group aged 20-29 than 40-49 ($p=0.0007$). Decreasing incidence rate with age was especially seen in MO subjects. There were 2,206 subjects reported having MO in 1994 and who had also completed the 2002 survey. The average annual incidence rate of MA in these subjects was 25.8 PYs (95% CI: 23.5 to 28.3, $n_{crude}=456$).

Table 3. The sex-specific average annual incidence rates per 1000 person years (PYs) from 1994 to 2002 of migraine, migraine with aura (MA) and migraine without aura (MO) in 16,442 subjects aged 20 to 49.

	All subjects			Women			Men		
	1000PYs	95% CI	n,crude	1000PYs	95% CI	n,crude	1000PYs	95% CI	n,crude
Migraine	17.6	16.9-18.4	2,318	23.4	22.3-24.6	1,617	11.2	10.4-12.1	701
MA	5.6	5.2-6.1	741	8.0	7.4-8.7	553	3.0	2.6-3.5	188
MO	12.0	11.4-12.6	1,577	15.4	14.5-16.4	1,064	8.2	7.5-9.0	513

Discussion

The present study demonstrated a significant increase of self-reported migraine prevalence in the Danish young adult population from 1994 to 2002. The increase was especially evident in

1
2
3 MA and the increase in MO was also significant. The increase was primarily seen in the
4
5 population older than 32 years.
6
7

8 9 *Migraine lifetime prevalence*

10
11 The lifetime prevalence has been estimated in several population-based studies with large
12
13 variation between 11.2% and 27.5% in questionnaire-based studies and between 12% and
14
15 19% in interview-based studies in the developed countries.[3] The variation seen may be due
16
17 to difference in methodology. One might wonder why the prevalence of lifetime migraine in
18
19 2002 was unexpectedly high in our study compared to the lifetime prevalence in the other
20
21 developed countries. However, comparison of the prevalence found in other large-scale
22
23 comparable European population-based questionnaire studies our results were similar, for
24
25 references see.[4] This was true for both men and women. One explanation could be that
26
27 patients in Europe were more likely to receive a medical diagnosis than for example in the
28
29 US.[19] Very few studies have estimated the lifetime prevalence of migraine subtypes. A
30
31 previous Danish study.[20] showed a higher lifetime prevalence of MA than the one we
32
33 found in 1994 (6% vs. 4.8%). However, the prevalence of MO was lower than ours (8% vs.
34
35 11.3%). Another study found lower prevalence rates of both MA and MO, 3.3% and
36
37 7.1%.[21] We expected to see increasing lifetime prevalence with advancing age, however,
38
39 the prevalence was decreasing after the 5th decade. A decrease was especially seen in MA
40
41 whereas the prevalence in MO reached a plateau. This is likely due to recall bias as discussed
42
43 previously.[22-23] MA patients tend to neglect having migraine compared to MO because
44
45 MA attacks are less frequent and less severe.[24] That may explain the pronounced difference
46
47 in MA and MO patients.
48
49
50
51
52

53
54
55
56 *Is the migraine prevalence increasing?*
57
58
59
60

1
2
3 We found a 32% increase in the lifetime prevalence of migraine in a period of 8 years.
4
5 Change in lifetime as well as 1-year prevalence has previously been investigated in replicate
6
7 studies. A large-scale study investigating subjects aged 12 and up found that the lifetime
8
9 prevalence of migraine increased significantly by 16% over a period of 4 years in women
10
11 (10.1% vs. 11.7%, $p \leq 0.01$) but a non-significant decrease was seen in men (4.3% vs. 3.8%).[6]
12
13
14 The group of 25 to 54 years which is more comparable with our study population also
15
16 showed a significant increase in women and a non-significant increase in men. Our study
17
18 showed a significant increase in both sexes. The difference seen may be due to different study
19
20 population or sample size. A Danish study investigating both lifetime and 1-year prevalence
21
22 of migraine from 1989 to 2001 found no significant changes, as only a tendency towards an
23
24 increase was observed (14.5% vs. 18.4%, difference -3.9, 95% CI: -11.5 to 3.8 for the
25
26 lifetime prevalence; 11.3% vs. 15.5%, difference -4.1, 95% CI: -11.1 to 2.8 for the 1-year
27
28 prevalence).[8] This increasing trend was also seen for 1-year prevalence in women (15.6%
29
30 vs. 23.5%, $p=0.14$). However, this study had a small sample size ($n=211$ and 207) and must
31
32 be interpreted with caution. A recent large-scale population-based study found a small
33
34 increase in the 1-year prevalence (12.1% vs. 13.2%, $p < 0.001$).[9] A marked increase in 6-
35
36 months prevalence over a period of 28 years (1.9% to 5.7%) was found in a study
37
38 investigating 7-year old children.[25] Other large-scale studies demonstrated no change in
39
40 migraine prevalence over time.[5,7] A true increase in prevalence would be attributed to
41
42 rising incidence. However, part of the increase may also be due to rising public awareness of
43
44 migraine or increased medical consultation resulting in an increased rate of physician
45
46 diagnosis.[26,27] We do not know of any approaches to increase awareness of migraine in
47
48 Denmark. However, an increase in medical consultation has been shown.[28] Subjects born
49
50 in 1953-82 were invited to participate in both surveys. This means that the group of subjects
51
52 who did participate in both surveys would have experienced the migraine questions already.
53
54
55
56
57
58
59
60

1
2
3 It is possible that these subjects became more aware of migraine to the second survey. On
4
5 balance our data convincingly show an increase in prevalence but the size of the increase may
6
7 not be as high as our finding of 32%. Due to the short time span of 8 years, this must be
8
9 caused by environmental factors and not by genes. Mutations cannot increase the migraine
10
11 prevalence so quickly in a general population. Currently we do not know about any potential
12
13 environmental factors or its nature or course. Some factors such as social economic status,[5]
14
15 smoking and alcohol,[29] have been suggested based on cross-sectional studies but to our
16
17 knowledge very few longitudinal studies have investigated risk factors for migraine. One
18
19 cohort study reported that smokers have a higher risk of developing self-reported
20
21 migraine.[30] Apparently, the need of more longitudinal studies is wanted.
22
23
24
25

26 27 *Migraine 1-year prevalence*

28
29 Although our lifetime prevalence was high, the 1-year prevalence was found to match the
30
31 lower range of the prevalence rates in Europe based on large-scale comparable questionnaire
32
33 studies (11.6 to 16.3%, 7.5 to 9.5% in men and 15.6 to 25% in women) as well as in
34
35 interview-based studies.[4] Comparing the 1-year migraine prevalence in 2002 with the
36
37 lifetime prevalence in 2002, we found that more than 50% reporting lifetime migraine did not
38
39 experience attacks during the last year. This speaks for a favourable course of migraine. Only
40
41 few studies[24,27,31-34] have investigated the 1-year prevalence of migraine subtypes
42
43 showing a range for MA of 0.6% to 3.7% in men and 3.6% to 10.8% in women and for MO
44
45 2% to 7.3% and 7.5% to 11.9%, respectively. Our prevalence estimates were similar to those
46
47 found previously in Denmark and The United Kingdom.[24,33] The American Migraine
48
49 study revealed increasing prevalence in both male and female subjects from age 12 until
50
51 approximately age 40, after which a decreasing prevalence was noted.[35] This is in keeping
52
53 with our findings (see figure 1.A-C).
54
55
56
57
58
59
60

Incidence

A great variation is found in the literature for the incidence rate of migraine in the adult population (1.4 to 5.0 per 1000 PYs in men and 2.9 to 22 per 1000 PYs in women).[36-39] Our incidence rate in women is in keeping with previous findings, however, the rate in men is somewhat higher. A previous small-scale study in Denmark found an incidence of 8.1 per 1000 PYs in 2001 in subjects aged 25 to 64.[40] We found an annual incidence rate of 17.6 per 1000 PYs for migraine. The difference seen could be due to different methodology or that our population was younger (20 to 49 years old).

Methodological considerations

It was possible in this study to differentiate between MA and MO because of the use of validated diagnostic questions.[18] Furthermore, it was possible to subdivide between men and women and to distinguish between age groups because of the large sample size. However, the present study also has weaknesses. The validation of the two questions used to identify migraine cases showed that self-reported migraine was only correct in 74.5% of cases and furthermore approximately 23.8% of the migraine patients were not identified. Thus, our estimates would tend to be conservative. However, the sensitivity of our questions was higher than the sensitivity of an ICHD-II modified questionnaire[9] therefore our questions should be valid as a tool for identifying migraine and determining the prevalence and incidence.

Conclusions

Our most important finding was a substantial increase in the lifetime prevalence of [self-reported](#) migraine in Denmark from 1994 to 2002 confirming previous studies. Part of

1
2
3 the increase may be due to increased medical consultation resulting in an increased rate of
4 physician diagnosis or awareness due to [previous](#) participation in the 1994 survey. It seems
5
6 pertinent to study the causes of the increase and to implement preventive measures.
7
8
9

10 11 12 **Acknowledgements**

13
14 We thank Secretary Jytte Duerlund for [her](#) assistance in carrying out the “Twin Omnibus
15
16 2002” study. She did not receive compensation for her assistance.
17
18
19

20 21 **Competing interest**

22
23 All authors declare that we have no significant competing financial, professional or personal
24
25 interests that might have influenced the performance or presentation of the work described in
26
27 this manuscript.
28
29
30

31 32 **Exclusive license statement**

33
34 The Corresponding Author has the right to grant on behalf of all authors and does grant on
35
36 behalf of all authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group
37
38 Ltd and its Licensees to permit this article to be published in BMJ Open and any other
39
40 BMJ PGL products to exploit all subsidiary rights, as set out in our licence (
41
42 http://group.bmj.com/products/journals/instructions-for-authors/wholly_owned_licence.pdf)
43
44 and the Corresponding Author accepts and understands that any supply made under these
45
46 terms is made by BMJ PGL to the Corresponding Author.
47
48
49

50 51 52 **Research ethics**

53
54 This study was a registry study based solely on questionnaires and did not require any
55
56 approval from the Ethics Committee according to national regulations.
57
58
59
60

Funding

The project was funded by the Department of Neurology Research Fund, Glostrup Hospital (grant number not applicable). The funding bodies had no role in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

References

1. Leonardi M, Steiner TJ, Scher AT, et al. The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). *J Headache Pain* 2005;**6**:429-40.
2. Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. *Eur Neuropsychopharmacol* 2011;**21**:718-79.
3. Stovner L, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. *Cephalalgia* 2007;**27**:193-210.
4. Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. *J Headache Pain* 2010;**11**:289-99.
5. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. *Headache* 2001;**41**:646-57.
6. Gilmour H, Wilkins K. Migraine. *Health Rep* 2001;**12**:23-40.
7. Henry P, Auray JP, Gaudin AF, et al. Prevalence and clinical characteristics of migraine in France. *Neurology* 2002;**59**:232-7.
8. Lyngberg AC, Rasmussen BK, Jorgensen T, et al. Has the prevalence of migraine and tension-type headache changed over a 12-year period? A Danish population survey. *Eur J Epidemiol* 2005;**20**:243-9.

- 1
2
3 9. Linde M, Stovner LJ, Zwart JA, et al. Time trends in the prevalence of headache
4 disorders. The Nord-Trondelag Health Studies (HUNT 2 and HUNT 3). *Cephalalgia*
5 2011;**31**:585-96.
6
7
- 8
9
10 10. Skytthe A, Kyvik K, Holm NV, et al. The Danish Twin Registry: 127 birth cohorts of
11 twins. *Twin Res* 2002;**5**:352-7.
12
- 13
14 11. Skytthe A, Kyvik K, Bathum L, et al. The Danish Twin Registry in the new
15 millennium. *Twin Res Hum Genet* 2006;**9**:763-71.
16
- 17
18 12. Ulrich V, Gervil M, Fenger K, et al. The prevalence and characteristics of migraine in
19 twins from the general population. *Headache* 1999;**39**:173-80.
20
- 21
22 13. Kyvik KO, Christensen K, Skytthe A, et al. The Danish Twin Register. *Dan Med Bull*
23 1996;**43**:467-70.
24
- 25
26 14. Kyvik KO, Green A, Beck-Nielsen H. The new Danish Twin Register: establishment
27 and analysis of twinning rates. *Int J Epidemiol* 1995;**24**:589-96.
28
- 29
30 15. Christensen K, Vaupel JW, Holm NV, et al. Mortality among twins after age 6: fetal
31 origins hypothesis versus twin method. *BMJ* 1995;**310**:432-6.
32
- 33
34 16. Kyvik KO, Green A, Beck-Nielsen H. Concordance rates of insulin dependent diabetes
35 mellitus: a population based study of young Danish twins. *BMJ* 1995;**311**:913-7.
36
- 37
38 17. Skadhauge LR, Christensen K, Kyvik KO, et al. Genetic and environmental influence
39 on asthma: a population-based study of 11,688 Danish twin pairs. *Eur Respir J*
40 1999;**13**:8-14.
41
- 42
43 18. Le H, Tfelt-Hansen P, Russell MB, et al. Co-morbidity of migraine with somatic
44 disease in a large population-based study. *Cephalalgia* 2011;**31**:43-64.
45
- 46
47 19. Lipton RB, Scher AI, Steiner TJ, et al. Patterns of health care utilization for migraine in
48 England and in the United States. *Neurology* 2003;**60**:441-8.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 20. Russell MB, Rasmussen BK, Thorvaldsen P, et al. Prevalence and sex-ratio of the
4
5 subtypes of migraine. *Int J Epidemiol* 1995;**24**:612-8.
6
- 7 21. Svensson DA, Ekblom K, Larsson B, et al. Lifetime prevalence and characteristics of
8
9 recurrent primary headaches in a population-based sample of Swedish twins. *Headache*
10
11 2002;**42**:754-65.
12
- 13 22. Bille B. A 40-year follow-up of school children with migraine. *Cephalalgia*
14
15 1997;**17**:488-91.
16
- 17 23. Rasmussen BK. Epidemiology of headache. *Cephalalgia* 1995;**15**:45-68.
18
- 19 24. Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an
20
21 epidemiological study. *Cephalalgia* 1992;**12**:221-8.
22
- 23 25. Sillanpaa M, Anttila P. Increasing prevalence of headache in 7-year-old schoolchildren.
24
25 *Headache* 1996;**36**:466-70.
26
- 27 26. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the
28
29 American Migraine Study. *Headache* 1998;**38**:87-96.
30
- 31 27. Lipton RB, Scher AI, Kolodner K, et al. Migraine in the United States: epidemiology
32
33 and patterns of health care use. *Neurology* 2002;**58**:885-94.
34
- 35 28. Lyngberg AC, Rasmussen BK, Jorgensen T, et al. Secular changes in health care
36
37 utilization and work absence for migraine and tension-type headache: a population
38
39 based study. *Eur J Epidemiol* 2005;**20**:1007-14.
40
- 41 29. Aamodt AH, Stovner LJ, Hagen K, et al. Headache prevalence related to smoking and
42
43 alcohol use. The Head-HUNT Study. *Eur J Neurol* 2006;**13**:1233-8.
44
- 45 30. Hozawa A, Houston T, Steffes MW, et al. The association of cigarette smoking with
46
47 self-reported disease before middle age: the Coronary Artery Risk Development in
48
49 Young Adults (CARDIA) study. *Prev Med* 2006;**42**:193-9.
50
51
52
53
54
55
56
57
58
59
60

- 1
- 2
- 3 31. Lampl C, Buzath A, Baumhackl U, et al. One-year prevalence of migraine in Austria: a
- 4 nation-wide survey. *Cephalalgia* 2003;**23**:280-6.
- 5
- 6
- 7 32. Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. *Cephalalgia*
- 8 1997;**17**:15-22.
- 9
- 10
- 11 33. Steiner TJ, Scher AI, Stewart WF, et al. The prevalence and disability burden of adult
- 12 migraine in England and their relationships to age, gender and ethnicity. *Cephalalgia*
- 13 2003;**23**:519-27.
- 14
- 15
- 16 34. Zivadinov R, Willheim K, Jurjevic A, et al. Prevalence of migraine in Croatia: a
- 17 population-based survey. *Headache* 2001;**41**:805-12.
- 18
- 19
- 20
- 21 35. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the
- 22 United States. Relation to age, income, race, and other sociodemographic factors. *JAMA*
- 23 1992;**267**:64-9.
- 24
- 25
- 26 36. Becker C, Brobert GP, Almqvist PM, et al. Migraine incidence, comorbidity and health
- 27 resource utilization in the UK. *Cephalalgia* 2008;**28**:57-64.
- 28
- 29
- 30 37. Breslau N, Davis GC, Andreski P. Migraine, psychiatric disorders, and suicide
- 31 attempts: an epidemiologic study of young adults. *Psychiatry Res* 1991;**37**:11-23.
- 32
- 33
- 34 38. Stang PE, Yanagihara PA, Swanson JW, et al. Incidence of migraine headache: a
- 35 population-based study in Olmsted County, Minnesota. *Neurology* 1992;**42**:1657-62.
- 36
- 37
- 38 39. Rozen TD, Swanson JW, Stang PE, et al. Increasing incidence of medically recognized
- 39 migraine headache in a United States population. *Neurology* 1999;**53**:1468-73.
- 40
- 41
- 42 40. Lyngberg AC, Rasmussen BK, Jorgensen T, et al. Incidence of primary headache: a
- 43 Danish epidemiologic follow-up study. *Am J Epidemiol* 2005;**161**:1066-73.
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54

55 Figure legends

56

57

58

59

60

1
2
3 Figure 1A-C. The age- and sex-specific 1-year prevalence of migraine and its subtypes in
4
5 2002.
6
7

8
9
10 Figure 2A-C. The age- and sex-specific lifetime prevalence of migraine and its subtypes in
11
12 1994.
13

14
15
16 Figure 3A-C. The age- and sex-specific lifetime prevalence of migraine and its subtypes in
17
18 2002.
19

20
21
22
23 Figure 4A-C. Comparison of lifetime prevalence rates of 1994 with 2002 for subjects aged 20
24 to 41.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60